One way tumors are able to grow is by forming new blood vessels that supply them with
nutrients and oxygen.
Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are
involved with the formation of new blood vessels.
Blocking these proteins may prevent the tumor cells or blood vessels from continuing to grow.
To determine whether sunitinib can cause tumors to shrink or stabilize in patients with
recurrent brain cancer.
Patients 18 years of age or older with brain cancer whose disease has worsened after standard
treatment with surgery, radiation.
Patients take a sunitinib pill once a day in 4-week treatment cycles. Treatment may continue
as long as the tumor remains stable or decreases in size and the side effects of treatment
Routine blood tests are done every 2 weeks during the first 8 weeks of treatment and then
every 4 weeks after that.
Magnetic resonance imaging (MRI) scans are done before starting treatment (at baseline) and
at the end of every 4-week cycle to monitor tumor growth.
Positron emission tomography (PET) scans are done at baseline and at the end of the first
Neurological and physical examinations are done at baseline, at week 2 of treatment and at
the end of every treatment cycle.
Health-related quality of life is assessed every 4 weeks.
Pregnancy tests, electrocardiograms and echocardiograms are repeated as needed.